Application of amur corktree bark extract in preparation of medicine for treating chronic nephrosis
By using Corundum extract to regulate renal function and metabolism, the problems of low uric acid reduction and large side effects of existing chronic kidney disease treatment drugs have been solved, and safer, more effective and multi-path prevention and treatment effects have been achieved.
Patent Information
- Application Number
- CN202411955994.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-28
- Publication Date
- 2025-03-14
AI Technical Summary
The current chronic kidney disease treatment drugs have low rates of lowering uric acid standards, and there are problems such as liver and renal function damage, increased risk of cardiovascular disease and poor patient compliance.
After mechanical powdering of Sichuan Huangbai Chinese medicinal materials, the extract obtained by reflux of 70% ethanol was used as the main ingredient for the preparation of chronic kidney disease drugs. The main components of this extract are alkaloids, flavonoids, terpenes and other compounds. By regulating the renal filtration and excretion function, it reduces the blood uric acid, creatinine, and urea nitrogen levels, inhibits the renal immune-inflammatory response, regulates glycolipid metabolism, and maintains the colon tissue barrier function.
It improves the rate of uric acid reduction, protects renal function, delays the progression of renal fibrosis, reduces the risk of cardiovascular disease, reduces liver function damage, improves patient compliance and quality of life, and maintains intestinal health and body immunity.
Smart Images
Figure CN119607079A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a new use of Phellodendron chinense, in particular to a new use of a Phellodendron chinense extract, and more specifically to a new use of the Phellodendron chinense extract in preparing a chronic kidney disease medicine. Background Art
[0002] Chronic kidney disease (CKD) is a type of disease characterized by renal function imbalance, renal inflammatory cell infiltration, tubular epithelial cell necrosis, tubular atrophy and interstitial fibrosis, which may eventually lead to renal failure. Uric acid nephropathy is a type of CKD, and its pathological basis is long-term uncontrollable hyperuricemia. When the blood urate concentration exceeds its solubility in the blood, urate precipitates in the form of monosodium urate crystals (MSU), which initiates the immune-inflammatory response of the kidney, aggravates renal function damage and renal fibrosis, and forms a vicious cycle. In addition, it has been confirmed that damage to the intestinal mucosal barrier is one of the important links that accelerate the progression of uric acid nephropathy.
[0003] Conventional treatment strategies for uric acid nephropathy include uric acid lowering and renal protection therapy, and commonly used drugs include allopurinol, febuxostat, etc. However, clinical treatment has found that the uric acid lowering rate of most patients is low, and these drugs have a variety of adverse reactions, such as liver and kidney damage, increased risk of cardiovascular disease, etc. These side effects reduce patient compliance. For example, allopurinol, as a first-line drug, needs to be metabolized by the kidneys. For patients with renal insufficiency, the dosage needs to be adjusted, and long-term use may cause liver damage.
[0004] In view of the side effects of existing therapeutic drugs and the poor patient compliance, it is urgent to develop new therapeutic drugs. The object of the present invention is to provide a new use of Phellodendron amurense extract in the preparation of drugs for the prevention and treatment of various chronic kidney diseases, in order to achieve a safer, more effective and multi-pathway prevention and treatment effect. Summary of the invention
[0005] The purpose of the present invention is to provide the use of Phellodendron amurense extract in the preparation of chronic kidney disease drugs, so as to solve the problems in the prior art such as low uric acid lowering target rate, liver and kidney function damage, increased risk of cardiovascular disease, and poor patient compliance.
[0006] The above technical purpose of the present invention is achieved through the following technical scheme: the use of Phellodendron chinense extract in the preparation of chronic kidney disease drugs, wherein the Phellodendron chinense extract is the Phellodendron chinense extract obtained by mechanically grinding the Phellodendron chinense Chinese medicinal material, extracting it twice with 70% ethanol reflux, and combining them.
[0007] The present invention is further configured as follows: the main components of the Phellodendron chinense extract are compounds such as alkaloids, flavonoids, and terpenes.
[0008] The present invention is further configured as follows: the Phellodendron chinense extract can reduce blood uric acid, creatinine and urea nitrogen by regulating the filtration and excretion function of the kidney.
[0009] The present invention is further configured as follows: the Phellodendron amurense extract can inhibit kidney immune-inflammatory response and delay the process of kidney fibrosis.
[0010] The present invention is further configured as follows: the Phellodendron amurense extract can regulate sugar and lipid metabolism, and long-term use will not induce liver damage.
[0011] The present invention is further configured as follows: the Phellodendron chinense extract can regulate the expression of tight junction proteins in colon tissue and maintain the barrier function of colon tissue.
[0012] By adopting the above technical scheme, the present invention uses the Sichuan Phellodendron chinense Chinese medicinal material to mechanically powder, and then uses 70% ethanol to reflux extract twice to obtain the Sichuan Phellodendron chinense extract, and the present invention provides a new treatment strategy. The main components of the Phellodendron chinense extract are alkaloid compounds, which have anti-inflammatory, antioxidant and metabolic regulating activities in pharmacology, providing a new perspective for the treatment of chronic kidney disease. The Phellodendron chinense extract of the present invention can simultaneously regulate the purine and uric acid metabolism of the intestinal and kidney target organs, effectively reduce the blood uric acid level, and improve the uric acid reduction rate. In addition, the Phellodendron chinense extract can also inhibit the immune-inflammatory response of the kidney and delay the process of renal fibrosis, which is crucial for protecting renal function and delaying the progression of chronic kidney disease. At the same time, the Phellodendron chinense extract helps to reduce the risk of cardiovascular diseases associated with chronic kidney disease by regulating sugar and lipid metabolism, and long-term use will not induce liver damage, which significantly improves the patient's compliance and quality of life. It is worth noting that the Phellodendron chinense extract can also increase the expression of tight junction proteins in colon tissue, thereby maintaining the barrier function of colon tissue, significantly improving the intestinal health and body immunity of patients, and thus delaying the progression of chronic kidney disease.
[0013] In summary, the present invention has the following beneficial effects:
[0014] 1. The Cortex Phellodendri extract provided by the present invention can effectively regulate the filtration and excretion function of the kidney through the pharmacological activity of its main component alkaloid compounds, reduce the levels of blood uric acid, creatinine, and urea nitrogen, and thus improve the rate of achieving the target of lowering uric acid. This mechanism helps to control the generation and excretion of uric acid from the source, reduce the formation of urate crystals, and alleviate the immune-inflammatory response of the kidney.
[0015] 2. The anti-inflammatory and antioxidant properties of the Phellodendron chinense extract provided by the present invention help protect renal function and slow down the progression of renal fibrosis, which is an important therapeutic advantage for patients with chronic kidney disease. In addition, long-term use of Phellodendron chinense extract will not induce liver damage, reduce drug side effects, and improve patient compliance, which is particularly important for patients with chronic kidney disease who require long-term management.
[0016] 3. The Phellodendron chinense extract of the present invention can not only directly act on the kidneys, but also regulate sugar and lipid metabolism, which is of great significance for reducing the risk of cardiovascular diseases associated with chronic kidney disease. By improving the overall metabolic status of patients, the Phellodendron chinense extract helps reduce the risk of cardiovascular diseases in patients with chronic kidney disease and improve the overall health status and quality of life of patients.
[0017] 4. The Phellodendron chinense extract provided by the present invention can not only directly act on the kidneys, but also increase the expression of tight junction proteins in colon tissue, thereby maintaining the barrier function of colon tissue and preventing harmful substances in the intestine from entering the blood circulation, such as pathogenic microorganisms and bacterial toxins. By maintaining the barrier function of the patient's intestine, the Phellodendron chinense extract helps the intestinal mucosal barrier of patients with chronic kidney disease and improves the patient's intestinal health and body immunity. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 is a flow chart of the preparation of the Phellodendron chinense extract in an embodiment of the present invention;
[0019] Figure 2 is a schematic diagram of liquid phase-mass spectrometry / mass spectrometry in an embodiment of the present invention;
[0020] Figure a is a base peak chromatogram of a typical sample in positive ion mode; Figure b is a base peak chromatogram of a typical sample in negative ion mode; Figure c is a pie chart of the categories to which the chemical components belong;
[0021] Figure 3 This is a HE staining image of kidney tissue pathology in a mouse model of uric acid nephropathy in an embodiment of the present invention;
[0022] Figure 4 is a Masson staining image of kidney tissue of a mouse model of uric acid nephropathy in an embodiment of the present invention;
[0023] Figure 5 Schematic diagram of the expression of tight junction proteins in the colon of uric acid nephropathy model mice in the embodiment of the present invention. DETAILED DESCRIPTION
[0024] In order to enable those skilled in the art to better understand the solution of the present invention, the technical solution of the present invention will be further described in detail below in conjunction with the embodiments of the present invention and the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.
[0025] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present invention can be combined with each other. The present invention will be described in detail below in conjunction with the embodiments.
[0026] Example 1: Preparation of Phellodendron chinense extract, such as Figure 1 As shown, the following steps are included:
[0027] Raw material preparation: Select Phellodendri Chinensis Cortex, the dried bark of Phellodendri Chinensis Schneid., a Rutaceae plant, collected in Baoxing County, Ya'an City, Sichuan Province, to ensure that it is free of mildew and insect pests to ensure the quality and efficacy of the extract. The bark of Phellodendri Chinensis Cortex should be dried, usually naturally dried in a well-ventilated environment for temperature-controlled drying to remove moisture and maintain the active ingredients of the medicinal material.
[0028] Mechanical powdering: Use a professional Chinese herbal medicine powdering machine. In this embodiment, a high-speed grinder is used for powdering to ensure that the bark of Sichuan Cortex Phellodendri is evenly crushed into fine powder. During the powdering process, attention should be paid to controlling the fineness of the powdering. After passing through an 80-mesh sieve, the Cortex Phellodendri medicinal material powder is obtained to facilitate the release of the active ingredients in the subsequent extraction process.
[0029] Ethanol reflux extraction: 70% ethanol aqueous solution was selected as the extraction solvent, because ethanol is a good solvent that can dissolve the alkaloid compounds in Phellodendron amurense. Weigh 800g of crude drug powder, add 10 times and 8 times the amount of 70% ethanol for reflux extraction twice, each time for 2 hours, to ensure the full extraction of the active ingredients.
[0030] Combined extracts: Combine the extracts obtained from the two reflux extractions and store them in glass containers to avoid using materials that may react with ethanol. The combined extracts should be processed as soon as possible to reduce the degradation or volatilization of the active ingredients.
[0031] Concentration and drying: Use a rotary evaporator to concentrate the combined extract into 150 mL of Chinese medicine extract (raw drug concentration is 5.33 g / ml) to remove most of the solvent. The temperature and pressure should be controlled during the concentration process to avoid high temperature causing the destruction of the active ingredients.
[0032] Quality Control: Liquid chromatography-mass spectrometry / mass spectrometry (LC-MS / MS) analysis technology was used to analyze the components of the extracted Phellodendron amurense extract to ensure the presence of various major components in the extract.
[0033] The analysis results were compared with the mass spectra of known alkaloid compounds in Phellodendron chinense, and the LC-MS / MS detection platform, public databases and self-built Chinese medicine material library were used for identification to verify the purity and quality of the extract. Figure 2 As shown, LC-MS / MS analysis can be used to quantitatively detect the content of the main components in the extract, providing a basis for the standardization of the preparation.
[0034] Example 2: Protective effect of Phellodendron amurense extract on kidneys in mice with uric acid nephropathy 1. Experimental animals
[0035] SPF male C57 / BL6J mice were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd. (License No.: SCXK (Xiang) 2021-0002) and fed in the SPF barrier system of the Experimental Animal Center of Sichuan Academy of Traditional Chinese Medicine (Use License No.: SYXK (Chuan) 2023-0100, indoor temperature 22 ± 2 ° C, relative humidity 50% ± 10%). After 3 days of adaptive feeding, they were used in the experiment.
[0036] 2. Experimental Materials
[0037] Fructose (Aladdin, specification: 2.5 kg); adenine (Sigma, specification: 25 g); allopurinol (Aladdin, specification: 5 g); uric acid assay kit (UA, batch number: 412230141), creatinine assay kit (Cr, batch number: 141124012), urea nitrogen assay kit (Urea, batch number: 141324013), aspartate aminotransferase assay kit (AST, batch number: 140224006), alanine aminotransferase assay kit (ALT, batch number: 140124018), glucose (Glu, batch number: 141524009), total cholesterol (TC, batch number: 141624009), triglyceride (TG, batch number: 141724006) were purchased from Shenzhen Mindray Animal Medical Technology Co., Ltd.; Mouse IL-1β ELISA kit (EXCell, specification: 96T), Mouse IL-6 ELISA kit (EXCell, specification: 96T, batch number: 022D-0530A); glutathione peroxidase (GSH-Px), total superoxide dismutase (SOD), and malondialdehyde (MDA) test kits were purchased from Nanjing Jiancheng Bioengineering Institute.
[0038] 3. Experimental instruments
[0039] Microplate reader (Tecan Sunrise, RC / ST), centrifuge (Sigma, D37520), fully automatic biochemical analyzer (Mindray, BS360S); upright optical microscope (Nikon, Japan, NIKON ECLIPSE E100); inverted fluorescence microscope (Zeiss, Axio Observer5); chemiluminescent gel imager (Tianneng, 4600); ultrapure water production system (Sichuan Youpu Ultrapure Technology Co., Ltd., UPH-I-40TNP); electronic balance (HZ Electronic Technology Co., Ltd., Connecticut, USA, PPT-A+100).
[0040] 4. Experimental Methods
[0041] 4.1 Grouping and Dosing
[0042] 40 C57 mice were randomly divided into blank group, model group (Model), allopurinol group (Allopurinol, 10mg / kg), low-dose group of Phellodendron chinense alcohol extract (L, 3.33g crude drug amount / kg), and high-dose group of Phellodendron chinense alcohol extract (L, 6.66g crude drug amount / kg), with 8 mice in each group. Except for the blank group, mice in the other groups drank fructose water freely for 3 weeks, and then gavaged with 40mg / kg of adenine for 1 week. Blood was collected from the orbital venous plexus to detect uric acid and creatinine levels, which were significantly higher than those in the blank group. One mouse in each group was extracted for kidney HE staining to determine the renal injury of the model mice, and then the corresponding drugs were continuously gavaged for 4 weeks, while continuing to drink fructose water freely (except the blank group).
[0043] 4.2 Observation of body weight and general condition
[0044] During the experiment, the animal's physical signs and other general conditions were observed regularly, and the body weights of the mice were recorded at 0d, 7d, 14d, and 28d after administration.
[0045] 4.3 Serum biochemical index detection
[0046] Each group of mice ate for 12 hours before the last administration. One hour after administration, blood was collected under anesthesia. The blood was kept at room temperature for 2 hours and centrifuged at 4°C, 3500rpm for 15 minutes to collect serum. The contents of serum UA, Cr, Urea, AST, ALT, Glu, TC, and TG were detected using an automatic biochemical analyzer. The remaining serum was used according to the instructions of the corresponding kit to detect the levels of MDA, SOD, and GSH-Px.
[0047] 4.4 Renal tissue pathological observation
[0048] After the mouse blood samples were collected, the kidneys were quickly separated on an ice plate, one side was fixed in a 4% paraformaldehyde solution, and then dehydrated, waxed, embedded and sliced. HE staining was then performed, and each sample tissue section was observed under an optical microscope, and representative pictures were collected for evaluation.
[0049] 4.5 Observation of renal tissue fibrosis
[0050] After the kidney samples were fixed, dehydrated, waxed, embedded and sliced, Masson staining was performed, and the tissue sections of each sample were observed under an optical microscope, and representative pictures were collected for evaluation. The collagen area in the sections was analyzed by Image J software to evaluate renal interstitial fibrosis. The renal collagen volume fraction (CVF) is the percentage of the collagen-positive blue area to the total area of renal tissue.
[0051] 4.6 Observation of colon pathology and tight junction protein expression
[0052] After collecting the feces in the colon, the colon samples of each group of mice were quickly cleaned in physiological saline, fixed in 4% paraformaldehyde solution, and routinely embedded in paraffin. After sectioning, HE staining was performed, and the tissue sections of each sample were observed under an optical microscope, and representative pictures were collected for evaluation. After tissue sectioning, the expression of colon tight junction proteins ZO-1 and Claudin-1 was detected by immunohistochemistry, and the tissue sections of each sample were observed under an optical microscope, and representative pictures were collected for evaluation. The expression of the corresponding protein was evaluated by analyzing the brown-yellow area in the section using Image J software.
[0053] 4.7 Statistical analysis
[0054] The data of quantitative data were expressed as mean ± standard deviation (x ± S). Graphpad Prism 9.5.0 was used for data analysis, and one-way analysis of variance was used for comparison among multiple groups. p < 0.05 was considered statistically significant.
[0055] 5 Results
[0056] As shown in Table 1 below, compared with the blank group, the blood uric acid, creatinine, and urea nitrogen of the uric acid nephropathy model mice increased significantly, and the difference was statistically significant (p<0.05 or p<0.01), indicating that the uric acid nephropathy model mice had hyperuricemia and renal damage. Compared with the model group, the blood uric acid and creatinine of the mice in the allopurinol group decreased significantly, and the difference was statistically significant (p<0.05 or p<0.01), but there was no significant effect on the blood urea nitrogen level, and the difference was not statistically significant (p>0.05), indicating that allopurinol can significantly restore the hyperuricemia of the uric acid nephropathy model mice. Compared with the model group, the serum uric acid and creatinine levels of mice in the high-dose group of Phellodendron amurense alcohol extract were significantly reduced, and the difference was statistically significant (p<0.05 or p<0.01). The blood urea nitrogen level showed a downward trend, but the difference was not statistically significant (p>0.05), indicating that Phellodendron amurense alcohol extract can significantly restore the hyperuricemia of uric acid nephropathy model mice; the creatinine levels of mice in the low-dose group of Phellodendron amurense alcohol extract were significantly reduced, and the difference was statistically significant (p<0.05 or p<0.01). The blood uric acid and blood urea nitrogen levels showed a downward trend, but the difference was not statistically significant (p>0.05).
[0057] Compared with the blank control group, the blood AST and ALT of mice in the uric acid nephropathy model showed a downward trend, but the difference was not statistically significant (p>0.05). It should be noted that compared with the model group, the blood AST and ALT of mice in the allopurinol group were significantly increased, and the difference was statistically significant (p<0.01), indicating that allopurinol may promote liver damage in uric acid nephropathy model mice. Compared with the model group, the blood ALT of mice in the low-dose group of Phellodendron chinense alcohol extract was significantly reduced, and the difference was statistically significant (p<0.05). In addition, compared with the allopurinol group, the blood AST and ALT of mice in the low- and high-dose groups of Phellodendron chinense alcohol extract were significantly reduced, and the difference was statistically significant (p<0.05).
[0058] The above results show that Phellodendron chinense alcohol extract can significantly restore hyperuricemia in uric acid nephropathy model mice and protect renal function. And long-term use will not induce liver damage in uric acid nephropathy model mice, indicating that the long-term application effect of Phellodendron chinense alcohol extract is better than allopurinol.
[0059] Table 1 Effects of Phellodendron chinense ethanol extract on liver and kidney function in uric acid nephropathy model mice
[0060]
[0061] Note: Compared with the model group, * p<0.05, ** p<0.01; compared with the allopurinol group, # p<0.05, ## p<0.01.
[0062] As shown in Table 2 below, compared with the blank group, the fasting blood glucose, total cholesterol, and triglycerides of the uric acid nephropathy model mice were significantly increased, and the difference was statistically significant (p<0.01), indicating that the high fructose and adenine-induced uric acid nephropathy model mice had abnormal glucose and lipid metabolism. Compared with the model group, the fasting blood glucose, total cholesterol, and triglycerides of the allopurinol group were significantly reduced, and the difference was statistically significant (p<0.01); the fasting blood glucose, total cholesterol, and triglycerides of the low and high dose groups of Phellodendron chinense alcohol extract were significantly reduced, and the difference was statistically significant (p<0.01). The above results show that Phellodendron chinense alcohol extract can correct the abnormal glucose and lipid metabolism of uric acid nephropathy model mice.
[0063] Table 2 Effects of Phellodendron chinense ethanol extract on blood glucose and blood lipids in uric acid nephropathy model mice
[0064]
[0065] Note: Compared with the model group, ** p<0.01.
[0066] As shown in Table 3 below, compared with the blank group, the blood GSH-Px, SOD, and MDA of the uric acid nephropathy model mice increased significantly, and the difference was statistically significant (p<0.01), indicating that the antioxidant system of the uric acid nephropathy model mice induced by high fructose and adenine was impaired. Compared with the model group, the blood GSH-Px and SOD of the mice in the allopurinol group increased significantly, and the difference was statistically significant (p<0.01); the blood GSH-Px and SOD of the mice in the low and high dose groups of Phellodendron chinense alcohol extract were significantly reduced, and the difference was statistically significant (p<0.05), and the MDA level was significantly reduced, and the difference was statistically significant (p<0.01). The above results show that Phellodendron chinense alcohol extract can restore the antioxidant system of uric acid nephropathy model mice.
[0067] Table 3 Effects of Phellodendron chinense ethanol extract on oxidative stress-related indicators in uric acid nephropathy model mice
[0068]
[0069] Note: Compared with the model group, * p<0.05, ** p<0.01.
[0070] like Figure 3As shown in the figure, HE staining results showed that the kidney tissue structure of the blank control group was normal and clear. In the model group, the kidney tissue of the mice showed obvious necrosis or partial shedding of tubular epithelial cells (blue arrows), inflammatory cell infiltration in the tubular interstitium (black arrows), and obvious periglomerular fibrosis (yellow arrows). In the allopurinol group, the kidneys of the mice showed obvious tubular dilatation (orange arrows), necrosis or partial shedding of tubular epithelial cells (blue arrows), inflammatory cell infiltration in the tubular interstitium (black arrows), and fibrosis around the glomeruli (yellow arrows), indicating that long-term use of allopurinol could not delay hyperuricemia-induced renal damage. In the Phellodendron chinense alcohol extract group, the kidneys of the mice showed obvious improvement, the degree of glomerular fibrosis was reduced, and some renal tubules were occasionally regenerated after damage (green arrows), and the infiltration of inflammatory cells in the tubular interstitium was reduced (black arrows), indicating that long-term use of Phellodendron chinense alcohol extract has a renal protective effect on uric acid nephropathy.
[0071] like Figure 4 As shown in the results of Masson staining, the blue staining degree of the renal tissue in the blank control group was lighter, and the collagen fiber positive area was lower (see Table 4). Compared with the blank control group, the blue staining degree of the renal tissue of the mice in the model group was higher, and the collagen fiber positive area was significantly increased, and the difference was statistically significant (p<0.01), indicating that the fibrosis degree of the uric acid nephropathy model mice was higher. Compared with the model group, the blue staining degree of the renal tissue of the mice in the allopurinol group was higher, and the collagen fiber positive area did not change significantly, and the difference was not statistically significant (p>0.05), indicating that allopurinol could not delay the process of renal fibrosis in hyperuricemia mice. On the contrary, compared with the model group, the blue staining degree of the renal tissue of the mice in the low and high dose groups of Phellodendron chinense alcohol extract was lower, and the collagen fiber positive area was significantly reduced, and the difference was statistically significant (p<0.01 or p<0.05). The above results show that Phellodendron chinense alcohol extract can delay the process of renal fibrosis in uric acid nephropathy model mice.
[0072] Table 4 Analysis of the effect of Phellodendron chinense alcohol extract on renal collagen fibrosis in uric acid nephropathy model mice
[0073] Group dose Collagen fiber positive area (%) Blank control group — <![CDATA[14.51±2.10 ** ]]> Model control group — 26.00±3.64 Allopurinol group 10mg / kg 25.23±2.49 Low-dose Phellodendron chinense group 3.33g / kg <![CDATA[18.77±2.34 * ]]> High-dose Phellodendron chinense group 6.66g / kg <![CDATA[15.36±2.01 ** ]]>
[0074] Note: Compared with the model group, *p<0.05, **p<0.01.
[0075] like Figure 5As shown in Table 5 below, the results of immunohistochemical staining showed that the expression of tight junction proteins Claudin-1 and ZO-1 in the colon tissue of the blank control group was significantly higher, while the expression of tight junction proteins in the model group mice was significantly reduced, and the difference was statistically significant (p<0.01 or p<0.05), indicating that the barrier function of the colon tissue of uric acid nephropathy model mice was impaired. Compared with the model group, the expression of tight junction proteins Claudin-1 and ZO-1 in the colon tissue of mice in the low and high dose groups of Phellodendron chinense alcohol extract was significantly increased, and the difference was statistically significant (p<0.01). The above results show that Phellodendron chinense alcohol extract can restore the barrier function of the colon tissue of uric acid nephropathy model mice.
[0076] Table 5 Effects of Phellodendron amurense alcohol extract on tight junction proteins in colon tissue of uric acid nephropathy model mice
[0077] Group dose Claudin-1 ZO-1 Blank control group — <![CDATA[1.63±0.27 * ]]> <![CDATA[38.28±3.6 ** ]]> Model control group — 0.42±0.37 4.58±0.41 Low-dose Phellodendron chinense group 3.33g / kg <![CDATA[1.68±0.1 ** ]]> <![CDATA[41.55±3.33 ** ]]> High-dose Phellodendron chinense group 6.66g / kg <![CDATA[3.58±1.54 ** ]]> <![CDATA[41.46±2.58 ** ]]>
[0078] Note: Compared with the model group, * p<0.05, ** p<0.01.
[0079] The above specific embodiments are merely explanations of the present invention and are not limitations of the present invention. After reading this specification, those skilled in the art may make modifications to the embodiments without any creative contribution as needed. However, such modifications are protected by the patent law as long as they are within the scope of the claims of the present invention.
Claims
1. Use of a Phellodendron chinense extract in preparing a drug for chronic kidney disease, characterized in that: The phellodendron amurense extract is obtained by mechanically grinding the phellodendron amurense Chinese medicinal material into powder, extracting it twice with 70% ethanol under reflux and combining the two extracts.
2. The new use of the Phellodendron chinense extract according to claim 1, characterized in that: The main components of the Phellodendron chinense extract are alkaloids, flavonoids, terpenes and other compounds.
3. The new use of the Phellodendron chinense extract according to claim 1, characterized in that: The Phellodendron chinense extract can reduce blood uric acid, creatinine and urea nitrogen by regulating the filtration and excretion functions of the kidney.
4. The new use of the Phellodendron chinense extract according to claim 1, characterized in that: The Phellodendron amurense extract can inhibit kidney immune-inflammatory response and delay the process of kidney fibrosis.
5. The new use of the Phellodendron chinense extract according to claim 1, characterized in that: The Phellodendron amurense extract can regulate sugar and lipid metabolism and will not induce liver damage when used for a long time.
6. The new use of the Phellodendron chinense extract according to claim 1, characterized in that: The Phellodendron amurense extract can increase the expression of tight junction proteins in colon tissue and maintain the barrier function of the intestinal mucosa.